{
    "pmcid": "8448731",
    "qa_pairs": {
        "How many unique binder families were identified through computational clustering in the study?": [
            "Over 800 potential binder families",
            "Over 1000 potential binder families",
            "Over 500 potential binder families",
            "Over 200 potential binder families"
        ],
        "How were the complementarity-determining regions (CDRs) of the nanobody library designed?": [
            "They were fully randomized based on natural nanobody sequences",
            "They were partially randomized with fixed sequences",
            "They were designed using a fixed template without randomization",
            "They were randomized only in CDR3"
        ],
        "What is the primary target for the nanobodies generated by the CeVICA platform?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What method does CeVICA use to link genotype and phenotype in nanobody selection?": [
            "Ribosome display",
            "Phage display",
            "Yeast surface display",
            "Bacterial display"
        ],
        "What was the result of affinity maturation on the selected nanobodies?": [
            "A neutralizing agent with a picomolar IC50",
            "A neutralizing agent with a nanomolar IC50",
            "A neutralizing agent with a micromolar IC50",
            "A neutralizing agent with a millimolar IC50"
        ]
    }
}